INDIANAPOLIS / Feb 22, 2024 / Business Wire / Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the Cowen 44th Annual Health Care Conference in Boston on March 5, at 2:50 p.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the webcast here.
For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation.
To listen to the live webcast, please visit Elevance Health’s website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Elevance Health’s recent filings with the SEC, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023.
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve more than 115 people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Last Trade: | US$541.91 |
Daily Change: | -2.49 -0.46 |
Daily Volume: | 458,704 |
Market Cap: | US$125.660B |
July 17, 2024 April 18, 2024 April 15, 2024 January 24, 2024 January 04, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB